

**Smart Matrix Limited****Smart Matrix enters into agreement with global biotherapeutics leader**

*Agreement secures scalable, long-term supply of critical ingredients for Smart Matrix<sup>®</sup> manufacture*

**21 April 2017, Smart Matrix Limited** ('SML' or 'the Company'), the advanced wound healing company, today announces that it has entered into a long-term supply agreement with CSL Behring, a world-leading biotherapeutics company known for developing and delivering products for serious medical conditions.

The agreement will ensure the supply of the key components - fibrinogen and thrombin - essential for the manufacture of Smart Matrix<sup>®</sup>, the Company's advanced wound care product that will enter its next human clinical trial early in 2018.

CSL Behring's manufacturing capacity means that this agreement will see SML's raw material supply secured for its pre-commercial clinical development phase and beyond into long-term commercial scale-up.

Andy Hill, Chief Executive Officer of Smart Matrix Limited, said: "I am delighted that we have been able to engage CSL Behring as our supplier of these critical ingredients for Smart Matrix<sup>®</sup> manufacture. CSL Behring has an excellent reputation as a high-quality supplier with unrivalled regulatory credentials in its field. In addition, CSL Behring has successfully supported small, early stage companies in securing the necessary international clearances to bring their products to market. With product supply secured, we continue to make good progress in the preparations ahead of our clinical trial next year."

For further information, please contact:

**Smart Matrix Limited**

Alan Henderson, Chairman

**info@smartmatrix.co.uk**

**FTI Consulting**

Mo Noonan / Simon Conway / Anna Foster

**Tel: +44 (0)20 3727 1000**

**About Smart Matrix Limited**

Smart Matrix Limited ('SML') was spun out of the Restoration of Appearance and Function Trust ("RAFT"), a medical research charity based at Mount Vernon hospital, Middlesex, UK, in late 2011.

SML is focused on the commercialisation of products from a proprietary platform technology developed by RAFT scientists based on a matrix manufactured from fibrin, a natural product of the healing process, and alginate, a product derived from seaweed and widely used in wound care products.

The first product developed from this platform is Smart Matrix<sup>®</sup>, a scaffold designed to help the body rapidly close wounds and regenerate lost skin. Smart Matrix<sup>®</sup> works by encouraging the growth of skin cells and new blood vessels, critical to healthy healing.

SML has an exclusive, world-wide license to Smart Matrix<sup>®</sup> and first right of refusal to license other products developed by RAFT that are based on the underlying platform technology. The potential applications of the platform include acute wound care, bone healing and regeneration, dental and soft-tissue repair.

For further information about SML please visit: [www.smartmatrix.co.uk](http://www.smartmatrix.co.uk)

For further information about RAFT please visit: [www.raft.ac.uk](http://www.raft.ac.uk)